Mutagenic Activity of Razoxane
Author Information
Author(s): R. Albanese, P.A. Watkins
Primary Institution: Imperial Chemicals Industries PLC, Pharmaceuticals Division
Hypothesis
Does razoxane (ICRF 159) exhibit mutagenic activity in various assays?
Conclusion
Razoxane was found to be non-mutagenic in the Salmonella/microsome assay but induced chromosomal aberrations in mammalian assays.
Supporting Evidence
- Razoxane did not increase mutation frequency in the Salmonella/microsome assay.
- An increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals.
- Razoxane induced abnormal chromosome condensation and structural chromosome aberrations in the Chinese hamster metaphase assay.
Takeaway
Razoxane is a cancer drug that doesn't cause mutations in bacteria but can cause changes in chromosomes in animals.
Methodology
The study used the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays to evaluate mutagenic activity.
Limitations
Cytotoxicity limited the analysis in some assays, affecting the ability to draw conclusions.
Participant Demographics
Mice and Chinese hamsters aged 10-12 weeks, weighing 15-30g and 20-33g respectively.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website